Decreased protein C activation in patients with fulminant hepatic failure

References

• Malchow-Moller A, Thomsen C, Hilden J, Matzen P, Mindehom L, Juhl E. Survival after jaundice: a prospective study of 1000 consecutive cases. Scand J Gastroenterol 1985; 20: 155–62
   PubMedGoogle Scholar
• Christensen E, Bremmelgaard A, Bahnsen M, Andreasen PB, Tygstrup N. Prediction of fatality in fulminant hepatic failure. Scand J Gastroenterol 1984; 19: 90–6
   PubMed Web of Science ®Google Scholar
• Lidofsky SD. Liver transplantation for fulminant hepatic failure. Gastroenterol Clin North Am 1993; 22: 257–69
   PubMed Web of Science ®Google Scholar
• Schiodt FV, Lee WM. Fulminant liver disease. Clin Liver Dis 2003; 7: 331–49
   PubMedGoogle Scholar
• O'Grady JG, Langley PG, Isola LM, Aledort LM, Williams R. Coagulopathy of fulminant hepatic failure. Semin Liver Dis 1986; 6: 159–63
   PubMedGoogle Scholar
• Langley PG, Forbes A, Hughes RD, Williams R. Thrombin-antithrombin III complex in fulminant hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcome. Eur J Clin Invest 1990; 20: 627–31
   PubMedGoogle Scholar
• Hirata K, Ogata I, Ohta Y, Fujiwara K. Hepatic sinusoidal cell destruction in the development of intravascular coagulation in acute liver failure of rats. J Pathol 1989; 158: 157–65
   PubMedGoogle Scholar
• Mochida S, Arai M, Ohno A, Yamanobe F, Ishikawa K, Matsui A, et al. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology 1999; 29: 1532–40
   PubMed Web of Science ®Google Scholar
• Higure A, Okamoto K, Hirata K, Todoroki H, Nagafuchi Y, Takeda S, et al. Macrophages and neutrophils infiltrating into the liver are responsible for tissue factor expression in a rabbit model of acute obstructive cholangitis. Thromb Haemost 1996; 75: 791–5
   PubMedGoogle Scholar
• Kume M, Hayashi T, Yuasa H, Tanaka H, Nishioka J, Ido M, et al. Bacterial lipopolysaccharide decreases thrombomodulin expression in the sinusoidal endothelial cells of rats: a possible mechanism of intrasinusoidal microthrombus formation and liver dysfunction. J Hepatol 2003; 38: 9–17
   PubMedGoogle Scholar
• Yamanobe F, Mochida S, Ohno A, Ishikawa K, Fujiwara K. Recombinant human tissue factor pathway inhibitor as a possible anticoagulant targeting hepatic sinusoidal walls. Thromb Res 1997; 85: 493–501
   PubMedGoogle Scholar
• Li C, Fung LS, Chung S, Crow A, Myers-Mason N, Phillips MJ, et al. Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection. J Exp Med 1992; 176: 689–97
   PubMed Web of Science ®Google Scholar
• Kaido T, Yoshikawa A, Seto S, Yamaoka S, Furuyama H, Arii S, et al. Pretreatment with soluble thrombomodulin prevents intrasinusoidal coagulation and liver dysfunction following extensive hepatectomy in cirrhotic rats. Thromb Haemost 1999; 82: 1302–6
   PubMedGoogle Scholar
• Suzuki K. Protein C. Molecular basis of thrombosis and hemostasis, KA High, HR Roberts. Marcel Dekker, New York 1995; 393–42
   Google Scholar
• Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29: S48–51
   Web of Science ®Google Scholar
• Taylor FB, Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918–25
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant human protein C Worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709
   PubMed Web of Science ®Google Scholar
• Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002; 88: 267–73
   PubMed Web of Science ®Google Scholar
• Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199–203
   PubMed Web of Science ®Google Scholar
• Shimizu S, Gabazza EC, Taguchi O, Yasui H, Taguchi Y, Hayashi T, et al. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 2003; 167: 1416–26
   PubMed Web of Science ®Google Scholar
• Langley PG, Williams R. The effect of fulminant hepatic failure on protein C antigen and activity. Thromb Haemost 1988; 59: 316–8
   PubMedGoogle Scholar
• Nagaki M, Iwai H, Naiki T, Ohnishi H, Muto Y, Moriwaki H. High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitis. J Infect Dis 2000; 182: 1103–8
   PubMedGoogle Scholar
• Kunze K. Metabolic encephalopathies. J Neurol 2002; 249: 1150–9
   PubMedGoogle Scholar
• Murakami K, Abe T, Miyazawa M, Yamaguchi M, Masuda T, Matsuura T, et al. Establishment of a new human cell line, LI90, exhibiting characteristics of hepatic Ito (fat-storing) cells. Lab Invest 1995; 72: 731–9
   PubMedGoogle Scholar
• Bernard PH, Le Bail B, Carles J, Fawaz R, Balabaud C, Rosenbaum J, et al. Morphology of hepatic stellate cells in patients with fulminant or subfulminant hepatitis requiring liver transplantation. J Submicrosc Cytol Pathol 1996; 28: 5–12
   PubMedGoogle Scholar
• Miyamoto S, Eguchi S, Sugiyama N, Kawazoe Y, Kamohara Y, Fujioka H, et al. Hepatic expression and serum levels of thrombomodulin reflect the extent of liver injury in rats with fulminant hepatic failure and extensive hepatectomy. Hepatol Res 2002; 22: 206–13
   PubMedGoogle Scholar
• Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988; 2: 72–4
   PubMed Web of Science ®Google Scholar
• Sekiyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 1994; 98: 71–7
   PubMed Web of Science ®Google Scholar
• Marra F, Grandaliano G, Valente AJ, Abboud HE. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 1995; 22: 780–7
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Matsumura F, Takeya M, Ichiguchi O, Kuratsu JI, Horiuchi T, et al. Monocyte chemoattractant protein-1 enhances expression of intercellular adhesion molecule-1 following ischemia-reperfusion of the liver in rats. Hepatology 1998; 27: 727–34
   PubMed Web of Science ®Google Scholar
• Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21: 397–416
   PubMed Web of Science ®Google Scholar
• Yoshikawa A, Kaido T, Seto S, Katsuura Y, Imamura M. Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats. J Hepatol 2000; 33: 953–60
   PubMedGoogle Scholar